NEW YORK, August 28, 2026, 10:22 EDT
- Cytokinetics stock dropped 5.0% to $74.00 as of 10:08 EDT, wiping out approximately $515 million in implied equity value.
- MYQORZO led to a 3.0-point improvement in symptom scores compared to placebo, and increased peak oxygen consumption by 0.67 ml/kg/min.
- The company intends to submit a supplemental FDA application for non-obstructive hypertrophic cardiomyopathy in the fourth quarter.
Cytokinetics shares fell after reporting the first positive Phase 3 trial results in non-obstructive hypertrophic cardiomyopathy. The market response indicates investors were looking for stronger clinical benefits from MYQORZO, the company’s new heart treatment.
Cytokinetics, Incorporated (NASDAQ: CYTK) was trading at $74.00 as of 10:08 EDT. The share price drop of 5.0% reduced its implied market capitalization by about $515 million.
ACACIA-HCM included 517 participants and achieved both primary outcomes at 36 weeks. MYQORZO raised the KCCQ symptom score by 11.4 points, compared with 8.4 for the placebo group. The difference versus placebo was 3.0 points ACACIA-HCM results.
Peak oxygen consumption increased by 0.64 ml/kg/min in the aficamten group, compared to a decrease of 0.03 with placebo, resulting in a 0.67 difference. Both primary endpoints surpassed the prespecified statistical criteria for the trial.
| Investor measure | MYQORZO | Placebo | Difference |
|---|---|---|---|
| KCCQ-CSS change, points | 11.4 | 8.4 | +3.0 |
| Peak VO2 change, ml/kg/min | +0.64 | -0.03 | +0.67 |
| At least one NYHA class improvement | 41.9% | 27.8% | +14.1 points |
| LVEF below 50% | 10.5% | 0.8% | +9.7 points |
The research also led to better functional class and lower levels of a cardiac-stress biomarker. There was no significant effect on left-atrial volume or duration until a first cardiovascular event occurred.
Chief Medical Officer Stephen Heitner described ACACIA-HCM as the “first-ever positive clinical trial in non-obstructive HCM.” The company plans to submit a supplemental application to the U.S. Food and Drug Administration in the fourth quarter.
Approval would widen a commercial franchise that remains in its initial phase. MYQORZO posted $25.3 million in product revenue for the second quarter. As of June 30, around 1,500 patients had been treated with the drug, and over 700 prescribers had issued prescriptions for it second-quarter update.
The launch is already driving significant expenditure. Selling and administrative expenses increased by 59% to $104.4 million. Management lifted its projection for total research and commercial costs in 2026 to between $860 million and $890 million.
Cytokinetics’ balance sheet allows the company operational flexibility. Following a $760 million share sale, cash and investments stood at roughly $1.7 billion. The company reported a net loss of $198.8 million in the second quarter.
Wall Street sentiment is positive. Out of 22 analysts polled, 20 recommend buying and two suggest holding, with an average price target of $109.90 analyst consensus. This target is 48.5% higher than the last quoted price on Friday.
The current discussion centers on commercial aspects rather than statistical ones. While a wider designation could expand MYQORZO’s potential market, doctors are faced with balancing small absolute endpoint benefits with the requirements for monitoring and the impact on cardiac function.
Risks: Regulators could assess the risk-benefit profile in another way. Among those receiving treatment, 10.5% had ejection fraction drop below 50%, compared with 0.8% in the placebo group. Incidence of serious adverse events was also higher with aficamten.
Related articles: Biotechnology
